In HIV+ patients with hematological malignancies, gene editing using CRISPR/Cas940 has been used to generate homozygous CCR5-Δ32 deletion in CD34+ cells to introduce HIV resistance. This evidence concerns the gene CCR5 and hematologic disorder.